Five-year financial record for the year ended 31 March Consolidated income statement 1 2 2011 2010 2009 2008 2007 m m m m m Revenue 111.4 98.5 84.8 75.0 45.7 Cost of sales 34.1 32.8 37.1 32.1 18.9 Gross profit 77.3 65.7 47.7 42.9 26.8 Operating and administrative expenses 45.3 29.3 20.6 13.8 18.9 Restructuring costs 3.8 0.7 10.9 8.1 1.0 Operating expenses 49.1 28.6 31.5 21.9 17.9 Research and development 32.1 26.7 21.2 12.2 9.0 Share of results of associates 0.3 0.4 0.7 0.7 Research and development expenses 32.1 27.0 21.6 12.9 9.7 Profit on disposal of assets and investments 1.5 1.1 2.6 0.4 2.7 Amounts written off associates and investments 1.4 3.4 1.0 Amortisation and impairment of business combination intangibles 10.0 9.1 3.0 Operating loss profit 13.8 2.1 9.2 8.5 0.9 Net financial income 3.0 7.0 2.1 2.2 1.7 Loss profit before tax 10.8 9.1 11.3 10.7 2.6 Tax 20.0 2.2 1.8 1.9 0.2 Profit loss after tax for the year 9.2 11.3 13.1 8.8 2.4 Basic and diluted earnings loss per share 3.4p 4.4p 7.1p 5.9p 1.6p Gross profit 1 2 2011 2010 2009 2008 2007 m m m m m Royalties from launched products 43.2 38.0 32.1 24.9 24.2 Income from new agreements and milestone payments 4.5 8.6 11.0 18.0 2.6 Gross profit from marketed products 26.6 19.1 4.6 Gross profit from Biocompatibles 3.0 Gross profit 77.3 65.7 47.7 42.9 26.8 1 The results for the year ended 31 March 2011 include the results of Biocompatibles from the date of acquisition, being 27 January 2011.
2 The results for the year ended 31 March 2009 include the results of Protherics from the date of acquisition, being 4 December 2008.
2 The statement of financial position for 31 March 2009 includes the assets and liabilities acquired from Protherics during the year.
Consolidated cash flow statement 1 2 2011 2010 2009 2008 2007 m m m m m Net cash used in from operating activities 12.0 5.8 1.8 13.4 3.1 Net cash used in from investing activities 5.5 2.6 21.8 0.8 5.4 Net cash from financing activities 0.6 1.4 0.1 0.8 Decrease increase in cash and cash equivalents 18.1 4.6 19.9 14.2 7.7 Effect of exchange rate fluctuations on cash held 0.8 0.2 1.3 0.2 0.3 Cash and cash equivalents at start of year 82.6 78.2 57.0 43.0 51.0 Cash and cash equivalents at end of year 63.7 82.6 78.2 57.0 43.0 1 The results for the year ended 31 March 2011 include the results of Biocompatibles from the date of acquisition, being 27 January 2011.
137 BTG plc Annual Report and Accounts 2011 Financials
